Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
GC Biopharma Corp (006280 KS)
Watchlist
115
Analysis
Health Care
•
South Korea
GC Biopharma is a biopharmaceutical company headquartered in Yongin, South Korea. It manufactures household medical drugs. The Company's product includes medicines for cold and fever, nutrition, antiseptic drug, and a lip balm.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
31 Oct 2016 16:11
Korea Stock Market Monthly Recap #7 - (October 2016)
The top events impacting the Korean stock market in October include the raid on Hanmi Pharm Co Ltd (128940 KS), disaster recall of Samsung...
Douglas Kim
Follow
390 Views
Share
bullish
•
Thematic (Sector/Industry)
•
14 Oct 2016 14:04
Internet of Things Will Change the World (Part 7) - 2016 IoT Exhibition & Conference in Seoul
We attended the 2016 IoT Exhibition & International Conference (Seoul) yesterday, which is the largest one for the IoT sector in Korea. We...
Douglas Kim
Follow
743 Views
Share
bullish
•
Thematic (Sector/Industry)
•
01 Aug 2016 15:19
Alpha Generation & Share Buybacks in Korea
Korean companies are showing increasing willingness to buyback shares. Korea Stock Exchange announced that from beginning of this year to as of 27...
Douglas Kim
Follow
689 Views
Share
bullish
•
Thematic (Sector/Industry)
•
07 Jul 2016 00:13
SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing
SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...
Sanghyun Park
Follow
3.6k Views
Share
bullish
•
Thematic (Sector/Industry)
•
05 Jul 2016 09:24
What the IPOs Completed in Korea Stock Exchange in 1H 2016 Reveal....
If you want to outperform the market, perhaps you should take a look at the IPO market in Korea. In the midst of difficult global IPO markets, the...
Douglas Kim
Follow
471 Views
Share
First
Previous
1
2
3
4
5
6
7
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.5
x